Cleveland BioLabs, Inc. (NASDAQ:CBLI) released its quarterly earnings results on Monday. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, Bloomberg Earnings reports. The firm had revenue of $0.21 million for the quarter. Cleveland BioLabs had a negative net margin of 111.40% and a negative return on equity of 28.45%.

Cleveland BioLabs (NASDAQ CBLI) opened at 2.70 on Tuesday. Cleveland BioLabs has a 52 week low of $1.22 and a 52 week high of $5.55. The company’s market capitalization is $30.45 million. The company’s 50 day moving average price is $2.76 and its 200-day moving average price is $2.63.

Separately, ValuEngine downgraded Cleveland BioLabs from a “hold” rating to a “sell” rating in a research note on Thursday, June 29th.

An institutional investor recently raised its position in Cleveland BioLabs stock. Vanguard Group Inc. raised its stake in shares of Cleveland BioLabs, Inc. (NASDAQ:CBLI) by 106.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 170,088 shares of the biotechnology company’s stock after buying an additional 87,885 shares during the period. Vanguard Group Inc. owned 1.51% of Cleveland BioLabs worth $501,000 at the end of the most recent reporting period. 1.70% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This article was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at

Cleveland BioLabs Company Profile

Cleveland BioLabs, Inc (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications.

Earnings History for Cleveland BioLabs (NASDAQ:CBLI)

Receive News & Ratings for Cleveland BioLabs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs Inc. and related companies with's FREE daily email newsletter.